Bruce L. Rogers. Ph.D. is the Founder, President, and CEO of Casterbridge Pharmaceuticals Inc.

 

Dr. Rogers has extensive experience in leadership and management of cross-functional R&D teams from early Discovery to end-of-Phase III clinical trials.  For much of his career he has DSCN3593 (2)been active in R&D-team Program Management, integration and planning.  He has comprehensive knowledge and significant hands-on experience in the core areas of Research, Pre-clinical safety, CMC, Formulation Development, Regulatory, Clinical Development, and Manufacturing.  He also successfully leveraged his knowledge of drug R&D to run his own successful consulting LLC (www.RogersPharmaConsulting.com) prior to founding Casterbridge Pharmaceuticals Inc.

Dr. Rogers has been intimately involved in small-molecule drug development in a succession of Biotech and Pharmaceutical companies in the greater-Boston biotech ecosystem, including ARIAD Pharmaceuticals, Vertex, Praecis, Oscient, and Wyeth (now Pfizer).

Prior to joining industry, Dr. Rogers was a postdoctoral fellow at MIT in Professor Susumu Tonegawa’s laboratory.

Dr. Rogers did a post-doctoral fellowship in Biochemistry at the M.D. Anderson Hospital and Tumor institute, University of Texas, Houston.

Dr. Rogers completed his Ph.D. in Biochemistry and Molecular Biology at the John Curtin School of Medical Research at the Australian National University, and did his undergraduate degree at the University of Western Australia.